TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06084988

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Allogenic Bone-Marrow-Derived Mesenchymal Stromal Cell Product (StromaForte)
Description: 50 x 106 allogeneic bone marrow (BM)-derived MSC formulated in 4 ml infusion solution of sodium chloride supplemented with human serum albumin to be given via ultrasound-guided intra-articular injection
Study: NCT05726474

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined exercise
Description: Patients will exercise for 40 minutes three times a week on an ergometric bicycle at 50-60% of VO2max, 60-70% of HRmax, 11-13 on the Borg scale, without ergometer at 50-60% of VO2max, 60-70% of HRmax, 11-13 on the Borg scale, without shortness of breathing difficulty. In addition, strength training will be performed (bench press, leg press, leg curl, leg machine, bench press, leg press, leg curl, leg curl, leg machine). leg curls, leg curls, rowing machine, triceps dips, pectoral pull-ups) twice a week. week. Strength training will be performed with 15 repetitions per exercise and per session, with a corresponding workload of 15 repetitions. session, with a workload corresponding to 60% to 65% of the 1-repetition maximum (1RM) measured at (1RM) measured at the beginning and at the end of the intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High interval training
Description: Patients will perform three training sessions per week. Each training session begins with a 10-minute warm-up at moderate intensity (corresponding to 50-60% of VO2max, 60-70% of HRmax, 11-13 on the Borg scale, no shortness of breath) before cycling, four 4-minute intervals at high intensity (corresponding to 85-90% of VO2max, 90-95% of HRmax, 15-17 on the Borg scale, shortness of breath). Each interval will be separated by 3 minutes of active pauses, with a HRmax of 50-70%. The training session will end with 3 minutes of cool down at moderate intensity (corresponding to 50-60%). moderate intensity (corresponding to 50-60% of VO2max, 60-70% of HRmax, 11-13 on the Borg scale, without difficulty). Borg scale, no shortness of breath). The total exercise time will be 40 minutes for the HIIT group.
Study: NCT05578378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: Cladribine combine with cytarabine will be intravenous on days 1-5; G-CSF will be hypodermic injection on day0-5,4 weeks per cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine
Description: Control arm~Patients in the control arm received the investigator's choice of one of the following three regimens:~FLAG:Fludarabine(30mg/m2)should be intravenous use on day 1-5, granulocyte colony-stimulating factor will be hypodermic injection using 300 μg per day on days 0-5,cytarabine (1.5 mg/m2) every 12 hours, intravenous infusion on day1-5,4 weeks per cycle.~a high-dose cytosine arabinoside-based regimen; a high-dose methotrexate-based regimen
Study: NCT05890482

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Islamic Trauma Healing
Description: Manualized, lay-led psychosocial intervention

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Islamic Trauma Healing
Description: Manualized, lay-led psychosocial intervention
Study: NCT05853172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK104
Description: Subjects will receive AK104 until disease progression or for up to 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Subjects will receive apatinib until disease progression or for up to 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Subjects will receive paclitaxel until disease progression or for up to 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: Subjects will receive S-1 until disease progression or for up to 6 cycles.
Study: NCT05217407

Intervention type: OTHER
Intervention: Genomic sequence
Description: Genomic sequence

Intervention type: OTHER
Intervention: Genomic sequence
Description: Genomic sequence
Study: NCT05926011

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RGn600
Description: RGn600 with a 10 Hz-pulsed wave mode light emission

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: RGn600 Sham
Description: RGn600 inactivated
Study: NCT06203028

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cyberbullying Awareness Training
Description: The 'Cyberbullying Awareness Training' program will be implemented in 2 sessions in 1 day for a total of 2 hours. The training program will be implemented in line with the headings 'Definition of cyberbullying, Cyberbullying tools and practices, Case studies on cyberbullying, Causes of cyberbullying, Academic, social, psychological and physical effects of cyberbullying, Coping strategies with cyberbullying'.
Study: NCT05015686

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Live attenuated varicella vaccines manufactured by Changchun BCHT Biotechnology Co.,Ltd
Description: live varicella-zoster virus in trehalose,human serum albumin,sodium glutamate,sucrose,glucose,carbamide,arginine and injection water per injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live attenuated varicella vaccines manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd
Description: live varicella-zoster virus in 0·5 mL of sucrose, sodium glutamate,sodium chloride,potassium chloride,sodium dihydrogen phosphate, potassium dihydrogen phosphate and injection water per injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium chloride and distilled water
Study: NCT04874831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: domatinostat in combination with avelumab
Description: domatinostat tablets and avelumab infusion
Study: NCT02546739

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CD19-CAR
Description: Cells extracted, followed by induction chemotherapy before CD19-CAR infusion (dose escalation.)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CD19-CAR
Description: Cells extracted, followed by induction chemotherapy before CD19-CAR infusion (dose escalation.)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CD19-CAR
Description: Cells extracted, followed by induction chemotherapy before CD19-CAR infusion (dose escalation.)
Study: NCT05182034

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SMUP-IA-01(low dose)
Description: A single knee administration of SMUP-IA-01(low-dose, 4.0 x 10\^6 cells/2mL)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SMUP-IA-01(mid dose)
Description: A single knee administration of SMUP-IA-01(mid-dose, 1.0 x 10\^7 cells/2mL)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Control Group Sodium chloride
Description: A single knee administration of Sodium chloride
Study: NCT05188560

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Action observation therapy
Description: Subject is asked to observe videos with motor contents

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: motor imagery
Description: mental simulation of a motor task
Study: NCT05234203

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HTB Rejuvenate
Description: 90 days of BID dosing of 2 capsules of HTB Rejuvenate
Study: NCT05898230

Intervention type: DEVICE
Intervention: Mitral Valve Replacement
Description: Mitral Valve Replacement with Carbomedics OptiForm Mitral Heart Valve
Study: NCT05156879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 75mg, one time/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drospirenone ethinyl estradiol
Description: 1 table/day, 21 consecutive days, 28 days as a cycle of use
Study: NCT05009940

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Graduated compression stockings
Description: Both GraduSOX and Sigvaris are graduated compression stockings. These exert the greatest degree of of compression at the ankle, and the level of compression gradually decreases up the garment.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Graduated compression stockings
Description: Both GraduSOX and Sigvaris are graduated compression stockings. These exert the greatest degree of of compression at the ankle, and the level of compression gradually decreases up the garment.
Study: NCT05752825

Intervention type: DIAGNOSTIC_TEST
Intervention: Nerve conduction test
Description: To fully examine all components of balance, nerve conduction will be tested using a handheld device called NC-stat DPN-Check in order to assess any peripheral neuropathy.

Intervention type: DIAGNOSTIC_TEST
Intervention: Visual acuity test
Description: Visual acuity will be tested using an automated refractometer (KR-800S Auto-kerato-refractometer, Topcon Healthcare, The Netherlands).

Intervention type: DIAGNOSTIC_TEST
Intervention: Visual acuity test
Description: Visual acuity will be tested using an automated refractometer (KR-800S Auto-kerato-refractometer, Topcon Healthcare, The Netherlands).
Study: NCT05773872

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionary
Description: In addition to the usual care, the patient will complete the following validated questionnaires :~SART (Sustained Attention to Response Task), IGT (Iowa Gambling Task), UPPS (Impulsive Behaviour Scale), TAS (Toronto Alexithymia Scale), BES (Basic Empathy Scale), FRET (Facial Emotions Recognition Task), ERF-CS, MASC (Movie for the Assessment of Social Cognition)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionary
Description: In addition to the usual care, the patient will complete the following validated questionnaires :~SART (Sustained Attention to Response Task), IGT (Iowa Gambling Task), UPPS (Impulsive Behaviour Scale), TAS (Toronto Alexithymia Scale), BES (Basic Empathy Scale), FRET (Facial Emotions Recognition Task), ERF-CS, MASC (Movie for the Assessment of Social Cognition)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionary
Description: In addition to the usual care, the patient will complete the following validated questionnaires :~SART (Sustained Attention to Response Task), IGT (Iowa Gambling Task), UPPS (Impulsive Behaviour Scale), TAS (Toronto Alexithymia Scale), BES (Basic Empathy Scale), FRET (Facial Emotions Recognition Task), ERF-CS, MASC (Movie for the Assessment of Social Cognition)
Study: NCT04871555

Intervention type: OTHER
Intervention: MRI
Description: structural imaging

Intervention type: OTHER
Intervention: MRI
Description: structural imaging

Intervention type: OTHER
Intervention: MRI
Description: structural imaging

Intervention type: OTHER
Intervention: MRI
Description: structural imaging

Intervention type: OTHER
Intervention: MRI
Description: structural imaging

Intervention type: OTHER
Intervention: MRI
Description: structural imaging
Study: NCT05197179

Intervention type: DRUG
Group type: OTHER
Intervention: FB2001
Description: Subjects will be administered with FB2001 by intravenous (IV) infusion

Intervention type: DRUG
Group type: OTHER
Intervention: FB2001
Description: Subjects will be administered with FB2001 by intravenous (IV) infusion

Intervention type: DRUG
Group type: OTHER
Intervention: FB2001
Description: Subjects will be administered with FB2001 by intravenous (IV) infusion

Intervention type: DRUG
Group type: OTHER
Intervention: FB2001
Description: Subjects will be administered with FB2001 by intravenous (IV) infusion

Intervention type: DRUG
Group type: OTHER
Intervention: FB2001
Description: Subjects will be administered with FB2001 by intravenous (IV) infusion

Intervention type: OTHER
Group type: OTHER
Intervention: FB2001 placebo
Description: Subjects will be administered with FB2001 by intravenous (IV) infusion

Intervention type: OTHER
Group type: OTHER
Intervention: FB2001 placebo
Description: Subjects will be administered with FB2001 by intravenous (IV) infusion

Intervention type: OTHER
Group type: OTHER
Intervention: FB2001 placebo
Description: Subjects will be administered with FB2001 by intravenous (IV) infusion

Intervention type: OTHER
Group type: OTHER
Intervention: FB2001 placebo
Description: Subjects will be administered with FB2001 by intravenous (IV) infusion

Intervention type: OTHER
Group type: OTHER
Intervention: FB2001 placebo
Description: Subjects will be administered with FB2001 by intravenous (IV) infusion
Study: NCT06358105

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Simulator-based training
Description: A two-day training program will be performed before starting their cath lab period as interventional cardiology fellows

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard training
Description: Standard master-apprentice training interventional cardiology fellows' program during their cath lab period
Study: NCT06637592

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Calcaneal taping
Description: Calcaneal taping is a method employed to offer assistance and relieve discomfort in the heel and ankle area. Start with a clean surface and apply first tape from lateral malleolus, pulling calcaneus in medial direction and attach to medial malleolus. Apply two more tapes in the same manner going distally. Apply an anchor tape at back of heel.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Windlass taping
Description: Begin by anchoring the tape just above the ball of the foot (metatarsal heads). Tear or cut a strip of tape, approximately 2-3 inches long, and place it horizontally around the foot, securing the starting point. Pull the tape diagonally across the bottom of the foot, aiming to support the arch. The tape should be applied with moderate tension to provide support without causing discomfort. While keeping tension on the tape, extend the big toe (great toe) upward. As the toe extends, the tape should tighten, activating the windlass mechanism and providing additional arch support.
Study: NCT04696939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab intravenous infusion was administered at a dose of 1200mg on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin intravenous infusion was administered at a dose of 75mg/m\^2 on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin intravenous infusion was administered at a dose of 75mg/m\^2 on Day 1 of each 21-day cycle.
Study: NCT04149210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorometholone 0.1% Oph Susp
Description: fluorometholone 0.1% one drop twice daily for four weeks, beginning with one drop just before trachomatous trichiasis surgery on the upper lid.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Artificial Tears
Description: Artificial tears (placebo) given one drop twice daily for four weeks, beginning with one drop just prior to trachomatous trichiasis surgery on the upper lid.
Study: NCT04696939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide intravenous infusion was administered at a dose of 100 mg/m\^2 on Day 1 of every 3-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Etoposide intravenous infusion was administered at a dose of 100 mg/m\^2 on Day 1 of every 3-day cycle.
Study: NCT04981431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elinzanetant (BAY3427080)
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elinzanetant (BAY3427080)
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elinzanetant (BAY3427080)
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elinzanetant (BAY3427080)
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elinzanetant (BAY3427080)
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elinzanetant (BAY3427080)
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral administration
Study: NCT05514678

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Stimulation Therapy
Description: CST consists of 14 sessions, each session with different themes. The materials used in therapy will differ according to the characteristics of each theme. For example; In the theme of physical games, one of the individuals will be selected by voting, and each individual will be asked to choose a song suitable for the theme and introduce himself/herself to the music accompaniment. Then, a small table game will be prepared with the rackets and ball used for table tennis, and individuals will be able to play a round of table tennis with the researcher and their groupmates. Sessions 10 min. introductory part, 25 min. activity section and 10 min. 45 minutes in total, including the ending. in progress.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Stimulation Therapy
Description: CST consists of 14 sessions, each session with different themes. The materials used in therapy will differ according to the characteristics of each theme. For example; In the theme of physical games, one of the individuals will be selected by voting, and each individual will be asked to choose a song suitable for the theme and introduce himself/herself to the music accompaniment. Then, a small table game will be prepared with the rackets and ball used for table tennis, and individuals will be able to play a round of table tennis with the researcher and their groupmates. Sessions 10 min. introductory part, 25 min. activity section and 10 min. 45 minutes in total, including the ending. in progress.
Study: NCT05082948

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Suture fixation of stent
Description: Esophageal stent will be placed in the standard of care fashion by the endoscopists using standard gastroscopes. Covered self-expanding metal stent will be placed as per endoscopist preference. After esophageal stent placement, endoscopic suturing will be performed in cases of patients randomized to suture fixation.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Non suture
Description: Standard placement of stent without suture fixation
Study: NCT03803657

Intervention type: DEVICE
Intervention: Monitoring of energy expenditure
Description: Continuous monitoring of energy expenditure.

Intervention type: DEVICE
Intervention: Monitoring of energy expenditure
Description: Continuous monitoring of energy expenditure.

Intervention type: DEVICE
Intervention: Monitoring of energy expenditure
Description: Continuous monitoring of energy expenditure.
Study: NCT05735379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deprescribing anticholinergic and sedative mediications
Description: Deprescribing plan targeting a reduction in Drug Burden Index score of ≥ 0.5
Study: NCT06449313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab-Rwlc
Description: 350 mg every 3 weeks, intravenously, on day 1 of a 21 day cycle for 4 cycles, then every 3 weeks after surgery for 1 year.
Study: NCT06318572

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychological intervention
Description: Patients will have 3 visits during the 7 weeks study length. On day -7 a first visit will be made verifying that inclusion criteria are met, the informed consent will be obtained and a rectal sensitivity test will be performed. A symptom questionnaire will be delivered to the patient for daily assessment of gastrointestinal symptoms.~On day 0, a stool sample will be collected and the symptom questionnaire will be reviewed to confirm inclusion criteria. Patients will begin the program of psychological intervention. A first, session of psychoeducation will be performed, and thereafter sessions of psychotherapy will be performed at home during 6 weeks.~At the end of treatment a last visit will be performed, collecting the symptoms scored during the last 7 days. A new stool sample will be collected and a rectal sensitivity study will be performed.~Severity of symptom questionnaire will be filled at the beginning, after 3 weeks, at the end of the treatment, at 3 months and at 6 months.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will have 3 visits during the 7 weeks study length. On day -7 a first visit will be made verifying that inclusion criteria are met, the informed consent will be obtained and a rectal sensitivity test will be performed. A symptom questionnaire will be delivered to the patient for daily assessment of gastrointestinal symptoms.~On day 0, a stool sample will be collected and the symptom questionnaire will be reviewed to confirm inclusion criteria. Patients will be instructed to take a capsule containing 0.5 g during 6 weeks.~At the end of treatment a last visit will be performed, collecting the symptoms scored during the last 7 days, A new stool sample will be collected and a rectal sensitivity study will be performed.~Severity of symptom questionnaire will be filled at the beginning, after 3 weeks, at the end of the treatment, at 3 months and at 6 months.
Study: NCT05470465

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo and Oxycodone
Description: Participants will receive placebo on days 1-21 for this treatment period. Oxycodone 10 mg (2 x 5 mg tablets) will be administered on days 6, 12, and 21 of this treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine and Oxycodone
Description: Participants will receive 40 mg paroxetine (2 x 20 mg tablets) on days 1-6 and 60 mg paroxetine (3 x 20 mg tablets) on days 7-21 for this treatment period. Oxycodone 10 mg (2 x 5 mg tablets) will be administered on days 6, 12, and 21 of this treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram and Oxycodone
Description: Participants will receive 20 mg escitalopram (2 x 10 mg tablets) on days 1-6 and 30 mg escitalopram (3 x 10 mg tablets) on days 7-21 for this treatment period. Oxycodone 10 mg (2 x 5 mg tablets) will be administered on days 6, 12, and 21 of this treatment period.